Lehigh Valley Health Network LVHN Scholarly Works

Department of Medicine

Burkitt Lymphoma Presenting as Left Lateral Rectus Palsy

Daniel Tseytlin DO Lehigh Valley Health Network, Daniel.Tseytlin@lvhn.org

Usman Shah MD Usman.Shah@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine Part of the <u>Hepatology Commons</u>, <u>Medical Sciences Commons</u>, and the <u>Oncology Commons</u>

Published In/Presented At

Tseytlin, D., & Shah, U. (April 29, 2014). Burkitt Llmphoma presenting as left lateral rectus palsy. Poster presented at: LVHN Research Day, Allentown PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Burkitt Lymphoma Presenting as Left Lateral Rectus Palsy Daniel Tseytlin, DO and Usman Shah, MD Lehigh Valley Health Network, Allentown, Pennsylvania

Case:

- A 43 year old male approximately 2 weeks prior to initial hospital presentation had some left eye pain while shoveling snow. The following day he woke up with left eye pain and double vision. He was seen by his primary doctor who prescribed him eye drops to reduce the pain, but still had double vision. On physical exam he was found to have impaired left eye abduction and ptosis consistent with palsy of cranial nerves VI and III, respectively. He did not have other neurologic pertinent findings such as slurred speech, weakness, numbness, facial weakness. He was evaluated in the emergency department. Initially, his CT scan did not show any acute stroke. His first MRI showed no evidence of acute infarct but showed abnormal soft tissue fullness in the cavernous sinus, especially on the left with concern for lymphoma or leukemia with metastatic disease or sarcoidosis. Basic laboratories including CBC and CMP were within normal limits apart from a mildly elevated AST of 42.
- CT scan of chest, abdomen, and pelvis to uncover the source of cavernous sinus masses. Results showed gastric antral wall thickening (Fig 1), extensive peritoneal carcinomatosis, reticulonodular opacities within the lungs, a pancreatic tail mass, small bilateral renal lesions and upper abdominal lymphadenopathy. The patient was initially treated with palliative brain radiation until diagnosed with lymphoma.





Figure 1. Gastric antral wall thickening on CT.

Figure 2. Peritoneal carcinomatosis on CT.

EGD and biopsy of the gastric lesion (Fig 3) as well as bone marrow biopsy (Fig 4, 5) of the iliac spine. Ki-67 index was very high >90%, c-MYC rearrangement was present, and his disease was determined to be stage IVB. Immunohistochemical studies:

CD20: (+)	Ki-67: (+) in
CD10: (+)	approx. 90%
BCL-6: (+)	of nuclei




Figure 3. Gastric biopsy showing "starry sky" pattern




Figure 4. Bone marrow showing lymphocytic vacuolization.

REFERENCES:

- 1. Kased, N et al. Niederhuber: Abeloff's Clinical Oncology, 5th Ed: 725.
- 2. Dunleavy, Kieron and Wilson, Wyndham H. Diagnosis and Treatment of Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma. Hoffman: Hematology: Basic Principles and Practice, 6th Ed: 1241-3.
- Wilson, Wyndham H. et al. Niederhuber: Abeloff's Clinical Oncology, 5th Ed: 2033, 2046. 3.
- Vaphiades, MS et al. J Neuroopthalmol 2005; 25 (3):249-250.
- 5. N Engl J Med. 1993;329:987-994.

Table 1. Diferential Diagnosis of Visual Disturbance				
Presentation	Differential			
Unilateral Painful Vision Disturbance	 Corneal abrasion or infection Acute angle-closure glaucoma Iritis/uveitis Optic neuritis Endophthalmitis Cavernous sinus thrombosis/mass 			
Diplopia	 Thyroid disease Cranial Neuropathyy (CN III, IV, VI) Neuromuscular disease (Myasthenia gravis) Botulism, Miller-Fisher Syndrome Encephalitis, Basilar meningitis Brianstem Stroke 			

BCL-2: (-/ dim focal+) BCL-1: (-) TdT: (-)




Figure 5. Bone marrow showing extensive necrosis.

Discussion:

- cancer.¹

	2. Ann Arbor Staging System			Risk	IPI Score	%	5-year
Stage	Cotswold Modification of A	rbor Classification		Group		Patients	ŎS
Т	Involvement of a single LN region or	lymphoid structure.		Low	0-1	35%	73%
Ш	Involvement of two or more LN regio of the diaphragm (Mediastinum is co but the hilar LNs are considered bilat	nsidered a single site, terally); the number of		Low- Intermed	2	27%	51%
	atomic sites should be indicated by a			High-	3	22%	43%
	III Involvement of LN regions on both sides of the diaphragm: III1 (with or without involvement of splenic hilar, celiac, or portal nodes) and III2 (with involvement of paraaortic, iliac, and mesenteric nodes.			Intermed	4 5	1.00/	0.00/
ш				High	4-5	16%	26%
	Fig	ure 6. Prognosis				ubtypes ⁵	
	Fig			/ariables f Prognostic In		ubtypes ⁵	
	100%	Internation				ubtypes ⁵	
	100%					ubtypes ⁵	
	100%	Internation	nal			ubtypes ⁵	
	100%	Internation	nal	Prognostic In		ubtypes ⁵	
	100% 75% 50%	Internation	nal	Prognostic In	dex (1993)	ubtypes ⁵	
	100%	Internation	nal	Prognostic In	dex (1993)		

Malignant metastasis to the central nervous system affects as many as 25% of patients with

Burkitt lymphoma (BL) is an uncommon² aggressive B-cell Lymphoma composed of rapidly proliferating B cells; it is considered the most highly aggressive NHL, with doubling times of 24 to 48 hours in some cases.³

BL is subdivided into Endemic, Sporadic, and immunodeficiency-associated.

Diagnosis of BL requires IHC staining for CD20+, CD10+ and TDT- with delineation from DLBCL by negativity for BCL-2.

 Translocation between MYC on chromosome 8 and one of three immmuoglobulin chain loci results in overexpression of the MYC protein causing deregulation of cellular growth.³ Initial presentation of BL as cavernous sinus syndrome is uncommon.⁴

Patient underwent treatment with HyperCVAD with intrathecal Methotrexate for CNS prophylaxis. The patient's prognosis was calculated using the International Prognostic Index (IPI) for aggressive lymphoma5. The IPI is a model for predicting outcome based on patient clinical characteristics prior to treatment. Patients are stratified according to risk with implications for treatment modalities. Those at high risk who are not effectively treated with current regimens may benefit from new clinical trial therapeutics. There are 5 adverse prognostic risk factors based on features of tumor growth potential, patient response to tumor, and ability to tolerate therapy: 1) age > 60 yo, 2) Ann Arbor Stage III/IV, 3) > 1 extranodal site, 4) Serum LDH > normal, 5) ECOG performance status >/= 2. (Score range 0 - 5).


The patient's IPI : 2 (Stage IVB and >1 extranodal site) indicated a 5 year overall survival of 51% and complete response rate of 67%.

International Prognostic Index (IPI)



A PASSION FOR BETTER MEDICINE."

610-402-CARE LVHN.org



55%

44%